TomCl的个人主页 - 老虎社区

TomCl

TomCl

暂无个人介绍

IP属地：未知

20关注

10粉丝

0主题

0勋章

2022-01-01

Sick

抱歉，原内容已删除

2021-12-23

Niceee nice investment and win

2021-11-12

Nixe

抱歉，原内容已删除

2021-06-25

SNDL?

Meme Stocks: How The Most Popular Have Performed in 2021

2021-06-17

$Sundial Growers Inc.(SNDL)$nice nieci

2021-06-16

Good good

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

2021-06-16

Good good

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

2021-06-16

Niceha

Cruise Stocks Gain As Wolfe Upgrades On Improving Demand

2021-06-16

Nicra

Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States

2021-06-16

$AAL 20230120 27.0 CALL(AAL)$nnice nieci

2021-06-15

$AAL 20230120 27.0 CALL(AAL)$nnice nieci

2021-05-19

Nicely//@TomCl: Nicely

抱歉，原内容已删除

2021-05-10

Nicely

抱歉，原内容已删除

2021-05-10

Nicely

5 Unbeatable Stocks to Buy for a Biden Bull Market

2021-05-10

Nice

抱歉，原内容已删除

2021-05-06

Nice nice

2021-05-06

$Sundial Growers Inc.(SNDL)$nnice

2021-05-06

$Sundial Growers Inc.(SNDL)$nnice nieci

2021-05-05

$Sundial Growers Inc.(SNDL)$nive nice

2021-05-05

Nice nice

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3571619533976102","uuid":"3571619533976102","gmtCreate":1608529903499,"gmtModify":1608956274360,"name":"TomCl","pinyin":"tomcl","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":10,"headSize":20,"tweetSize":81,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"02aa7f16703b4ce4ace6f1a7665789cc-3","templateUuid":"02aa7f16703b4ce4ace6f1a7665789cc","name":"知识航海家","description":"观看学堂课程满50节","bigImgUrl":"https://static.tigerbbs.com/21acbb5884e07b96522d8d84c4b7acea","smallImgUrl":"https://static.tigerbbs.com/e4e8dc2edfbfee912f4e68fe6c23b3f0","grayImgUrl":null,"redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":2006},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"93.25%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":6,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692252392,"gmtCreate":1641004346678,"gmtModify":1641004346848,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Sick","listText":"Sick","text":"Sick","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692252392","repostId":"2195481004","repostType":4,"isVote":1,"tweetType":1,"viewCount":1295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698018419,"gmtCreate":1640260145346,"gmtModify":1640260145486,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Niceee nice investment and win","listText":"Niceee nice investment and win","text":"Niceee nice investment and win","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698018419","isVote":1,"tweetType":1,"viewCount":980,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879655778,"gmtCreate":1636721723200,"gmtModify":1636721723314,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nixe","listText":"Nixe","text":"Nixe","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879655778","repostId":"2163488152","repostType":2,"isVote":1,"tweetType":1,"viewCount":1118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":122955354,"gmtCreate":1624594640978,"gmtModify":1631890890036,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"SNDL?","listText":"SNDL?","text":"SNDL?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122955354","repostId":"1147153207","repostType":4,"repost":{"id":"1147153207","kind":"news","pubTimestamp":1624592020,"share":"https://www.laohu8.com/m/news/1147153207?lang=&edition=full","pubTime":"2021-06-25 11:33","market":"us","language":"en","title":"Meme Stocks: How The Most Popular Have Performed in 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1147153207","media":"thestreet","summary":"Meme mania has been one of the most unexpected phenomena in the equities market in an already atypic","content":"<p>Meme mania has been one of the most unexpected phenomena in the equities market in an already atypical pandemic environment. The “meme attacks” have rarely been based on business fundamentals, but instead fueled by momentum and discussions on web forums that catalyze vicious rallies.</p>\n<p>Below, the Wall Street Memes channel lists some of the most popular meme stocks and how each has performed so far in 2021.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ac11607753df2d587eff881c858546dd\" tg-width=\"1200\" tg-height=\"798\" referrerpolicy=\"no-referrer\"><span>Figure 1: GameStop store.</span></p>\n<p><b>GME - GameStop Corp.</b></p>\n<ul>\n <li>Largest gain in 2021:<b>1,914%</b></li>\n <li>Largest loss in 2021:<b>-88%</b></li>\n <li>Peak price:<b>$347.51</b></li>\n <li>Current price:<b>$200.18</b>(at last check).</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/cc5e113c20912daf07551e09179fe9f2\" tg-width=\"1200\" tg-height=\"519\" referrerpolicy=\"no-referrer\"><b>AMC - AMC Theaters</b></p>\n<ul>\n <li>Largest gain in 2021:<b>2,850%</b></li>\n <li>Largest loss in 2021:<b>-72%</b></li>\n <li>Peak price:<b>$62.55</b></li>\n <li>Current price:<b>$55.14</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2e55df7c82d93174a0b4c088c17946a1\" tg-width=\"1200\" tg-height=\"533\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>BB - BlackBerry Limited</b></p>\n<ul>\n <li>Largest gain in 2021:<b>281%</b></li>\n <li>Largest loss in 2021:<b>-68%</b></li>\n <li>Peak price:<b>$25.10</b></li>\n <li>Current price:<b>$12.82</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/00f988c9dcc4545d783ac29b2061f44d\" tg-width=\"1200\" tg-height=\"525\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>CLNE - Clean Energy Fuels Corp.</b></p>\n<ul>\n <li>Largest gain in 2021:<b>137%</b></li>\n <li>Largest loss in 2021:<b>-59%</b></li>\n <li>Peak price:<b>$18.64</b></li>\n <li>Current price:<b>$11.22</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/42e24ea5dd3ca3f186eab5451fa7fcbc\" tg-width=\"1200\" tg-height=\"524\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>CLOV - Clover Health Investments</b></p>\n<ul>\n <li>Largest gain in 2021:<b>224%</b></li>\n <li>Largest loss in 2021:<b>-56%</b></li>\n <li>Peak price:<b>$22.15</b></li>\n <li>Current price:<b>$12.10</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddfd7742b5b929d9febee80c5926f08f\" tg-width=\"1200\" tg-height=\"507\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>CLF - Cleveland-Cliff</b></p>\n<ul>\n <li>Largest gain in 2021:<b>83%</b></li>\n <li>Largest loss in 2021:<b>-28%</b></li>\n <li>Peak price:<b>$24.44</b></li>\n <li>Current price:<b>$20.75</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/15c8accc6baf5e68f5a1088eb8a75c4d\" tg-width=\"1200\" tg-height=\"524\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>TLRY - Tilray Pharmaceuticals</b></p>\n<ul>\n <li>Largest gain in 2021:<b>610%</b></li>\n <li>Largest loss in 2021:<b>-78%</b></li>\n <li>Peak price:<b>$63.91</b></li>\n <li>Current price:<b>$17.23</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dc9ed19b51e752ceff9a6534d4afd089\" tg-width=\"1200\" tg-height=\"510\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>\n<p><b>NOK - Nokia Corporation</b></p>\n<ul>\n <li>Largest gain in 2021:<b>69%</b></li>\n <li>Largest loss in 2021:<b>-41%</b></li>\n <li>Peak price:<b>$6.55</b></li>\n <li>Current price:<b>$5.14</b>(at last check).</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/33e920e940ac016540520a46acbcb0d5\" tg-width=\"1200\" tg-height=\"511\" referrerpolicy=\"no-referrer\"><span>Google Finance</span></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meme Stocks: How The Most Popular Have Performed in 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeme Stocks: How The Most Popular Have Performed in 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-25 11:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/memestocks/other-memes/meme-stocks-how-the-most-popular-have-performed-in-2021><strong>thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meme mania has been one of the most unexpected phenomena in the equities market in an already atypical pandemic environment. The “meme attacks” have rarely been based on business fundamentals, but ...</p>\n\n<a href=\"https://www.thestreet.com/memestocks/other-memes/meme-stocks-how-the-most-popular-have-performed-in-2021\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.thestreet.com/memestocks/other-memes/meme-stocks-how-the-most-popular-have-performed-in-2021","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147153207","content_text":"Meme mania has been one of the most unexpected phenomena in the equities market in an already atypical pandemic environment. The “meme attacks” have rarely been based on business fundamentals, but instead fueled by momentum and discussions on web forums that catalyze vicious rallies.\nBelow, the Wall Street Memes channel lists some of the most popular meme stocks and how each has performed so far in 2021.\nFigure 1: GameStop store.\nGME - GameStop Corp.\n\nLargest gain in 2021:1,914%\nLargest loss in 2021:-88%\nPeak price:$347.51\nCurrent price:$200.18(at last check).\n\nAMC - AMC Theaters\n\nLargest gain in 2021:2,850%\nLargest loss in 2021:-72%\nPeak price:$62.55\nCurrent price:$55.14(at last check).\n\nGoogle Finance\nBB - BlackBerry Limited\n\nLargest gain in 2021:281%\nLargest loss in 2021:-68%\nPeak price:$25.10\nCurrent price:$12.82(at last check).\n\nGoogle Finance\nCLNE - Clean Energy Fuels Corp.\n\nLargest gain in 2021:137%\nLargest loss in 2021:-59%\nPeak price:$18.64\nCurrent price:$11.22(at last check).\n\nGoogle Finance\nCLOV - Clover Health Investments\n\nLargest gain in 2021:224%\nLargest loss in 2021:-56%\nPeak price:$22.15\nCurrent price:$12.10(at last check).\n\nGoogle Finance\nCLF - Cleveland-Cliff\n\nLargest gain in 2021:83%\nLargest loss in 2021:-28%\nPeak price:$24.44\nCurrent price:$20.75(at last check).\n\nGoogle Finance\nTLRY - Tilray Pharmaceuticals\n\nLargest gain in 2021:610%\nLargest loss in 2021:-78%\nPeak price:$63.91\nCurrent price:$17.23(at last check).\n\nGoogle Finance\nNOK - Nokia Corporation\n\nLargest gain in 2021:69%\nLargest loss in 2021:-41%\nPeak price:$6.55\nCurrent price:$5.14(at last check).\n\nGoogle Finance","news_type":1},"isVote":1,"tweetType":1,"viewCount":1301,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161221259,"gmtCreate":1623929962671,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","text":"$Sundial Growers Inc.(SNDL)$nice nieci","images":[{"img":"https://static.tigerbbs.com/fab74b2cd1a99b5693d5411f077730f3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/161221259","isVote":1,"tweetType":1,"viewCount":1381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163050271,"gmtCreate":1623854239793,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163050271","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00467":"联合能源集团","MOLN":"Molecular Partners AG","00626":"大众金融控股","UBCP":"联合合众银行","AFG":"美国金融集团有限公司"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163027475,"gmtCreate":1623854226797,"gmtModify":1631890890044,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163027475","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00467":"联合能源集团","MOLN":"Molecular Partners AG","00626":"大众金融控股","UBCP":"联合合众银行","AFG":"美国金融集团有限公司"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163027172,"gmtCreate":1623854206696,"gmtModify":1631890890047,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Niceha","listText":"Niceha","text":"Niceha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163027172","repostId":"1109608534","repostType":4,"repost":{"id":"1109608534","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623852639,"share":"https://www.laohu8.com/m/news/1109608534?lang=&edition=full","pubTime":"2021-06-16 22:10","market":"us","language":"en","title":"Cruise Stocks Gain As Wolfe Upgrades On Improving Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1109608534","media":"Tiger Newspress","summary":"Shares of the largest cruise operators, namely Royal Caribbean, Norwegian Cruise Line and Carnival, ","content":"<p>Shares of the largest cruise operators, namely Royal Caribbean, Norwegian Cruise Line&nbsp;and Carnival, were up in&nbsp;moring&nbsp;trading on an upgrade by Wolfe Research.</p>\n<p>Early signs of customer demand for the return of vacations at sea should make investors more bullish on cruise stocks, according to Wolfe Research.</p>\n<p>The cruise industry was one of the hardest hit by the pandemic, with voyages being stopped around the world, but with widespread vaccinations in the U.S., the major companies have plans toresume American operations over the summer.</p>\n<p>Analyst Greg Badishkanian upgraded&nbsp;Carnival,Royal Caribbean&nbsp;and&nbsp;Norwegian Cruise Line Holdingsto outperform from peer perform, saying in a note to clients on Wednesday that early indications pointed to a strong restart for the industry.</p>\n<p>“Our checks suggest improving booking / pricing trends out of North America over the past month, with stronger trends over the past week. While there is some lingering uncertainty surrounding the U.S. restart (CDC / Florida, etc.), we view those unknowns as largely transitory when viewed against the broader reopening backdrop,” the note said.</p>\n<p>Bookings and demand are running ahead of pre-pandemic levels, according to Wolfe.</p>\n<p>“Cumulative 2022 bookings are now up approx. +10% to +15% versus 2019 levels with signs of improving 1Q demand (especially in January). Pricing is up in the +15% to 25% range vs. 2019 before factoring in [future cruise credits],” the note said.</p>\n<p>Wolfe has price targets of $32 per share for Carnival, $96 for Royal Caribbean and $36 for Norwegian. Those represent upside of roughly 12%, 8% and 17%, respectively.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cruise Stocks Gain As Wolfe Upgrades On Improving Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCruise Stocks Gain As Wolfe Upgrades On Improving Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-16 22:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of the largest cruise operators, namely Royal Caribbean, Norwegian Cruise Line&nbsp;and Carnival, were up in&nbsp;moring&nbsp;trading on an upgrade by Wolfe Research.</p>\n<p>Early signs of customer demand for the return of vacations at sea should make investors more bullish on cruise stocks, according to Wolfe Research.</p>\n<p>The cruise industry was one of the hardest hit by the pandemic, with voyages being stopped around the world, but with widespread vaccinations in the U.S., the major companies have plans toresume American operations over the summer.</p>\n<p>Analyst Greg Badishkanian upgraded&nbsp;Carnival,Royal Caribbean&nbsp;and&nbsp;Norwegian Cruise Line Holdingsto outperform from peer perform, saying in a note to clients on Wednesday that early indications pointed to a strong restart for the industry.</p>\n<p>“Our checks suggest improving booking / pricing trends out of North America over the past month, with stronger trends over the past week. While there is some lingering uncertainty surrounding the U.S. restart (CDC / Florida, etc.), we view those unknowns as largely transitory when viewed against the broader reopening backdrop,” the note said.</p>\n<p>Bookings and demand are running ahead of pre-pandemic levels, according to Wolfe.</p>\n<p>“Cumulative 2022 bookings are now up approx. +10% to +15% versus 2019 levels with signs of improving 1Q demand (especially in January). Pricing is up in the +15% to 25% range vs. 2019 before factoring in [future cruise credits],” the note said.</p>\n<p>Wolfe has price targets of $32 per share for Carnival, $96 for Royal Caribbean and $36 for Norwegian. Those represent upside of roughly 12%, 8% and 17%, respectively.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RCL":"皇家加勒比邮轮","NCLH":"挪威邮轮","CCL":"嘉年华邮轮"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109608534","content_text":"Shares of the largest cruise operators, namely Royal Caribbean, Norwegian Cruise Line and Carnival, were up in moring trading on an upgrade by Wolfe Research.\nEarly signs of customer demand for the return of vacations at sea should make investors more bullish on cruise stocks, according to Wolfe Research.\nThe cruise industry was one of the hardest hit by the pandemic, with voyages being stopped around the world, but with widespread vaccinations in the U.S., the major companies have plans toresume American operations over the summer.\nAnalyst Greg Badishkanian upgraded Carnival,Royal Caribbean and Norwegian Cruise Line Holdingsto outperform from peer perform, saying in a note to clients on Wednesday that early indications pointed to a strong restart for the industry.\n“Our checks suggest improving booking / pricing trends out of North America over the past month, with stronger trends over the past week. While there is some lingering uncertainty surrounding the U.S. restart (CDC / Florida, etc.), we view those unknowns as largely transitory when viewed against the broader reopening backdrop,” the note said.\nBookings and demand are running ahead of pre-pandemic levels, according to Wolfe.\n“Cumulative 2022 bookings are now up approx. +10% to +15% versus 2019 levels with signs of improving 1Q demand (especially in January). Pricing is up in the +15% to 25% range vs. 2019 before factoring in [future cruise credits],” the note said.\nWolfe has price targets of $32 per share for Carnival, $96 for Royal Caribbean and $36 for Norwegian. Those represent upside of roughly 12%, 8% and 17%, respectively.","news_type":1},"isVote":1,"tweetType":1,"viewCount":704,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163024709,"gmtCreate":1623854195601,"gmtModify":1631890890052,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicra","listText":"Nicra","text":"Nicra","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163024709","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00467":"联合能源集团","MOLN":"Molecular Partners AG","00626":"大众金融控股","UBCP":"联合合众银行","AFG":"美国金融集团有限公司"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163025516,"gmtCreate":1623854162235,"gmtModify":1631886970139,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","text":"$AAL 20230120 27.0 CALL(AAL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/e8776237d83ec54343b68473ba20ec70","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163025516","isVote":1,"tweetType":1,"viewCount":896,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187159347,"gmtCreate":1623747510689,"gmtModify":1631886970169,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/AAL\">$AAL 20230120 27.0 CALL(AAL)$</a>nnice nieci","text":"$AAL 20230120 27.0 CALL(AAL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/ffcf7ba8b7f8e31930df0f23dbeff0b4","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/187159347","isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":197025498,"gmtCreate":1621412512814,"gmtModify":1631890890051,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely//<a href=\"https://laohu8.com/U/3571619533976102\">@TomCl</a>: Nicely","listText":"Nicely//<a href=\"https://laohu8.com/U/3571619533976102\">@TomCl</a>: Nicely","text":"Nicely//@TomCl: Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/197025498","repostId":"2134686276","repostType":4,"isVote":1,"tweetType":1,"viewCount":383,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190216986,"gmtCreate":1620622845345,"gmtModify":1631890890054,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/190216986","repostId":"2134686276","repostType":4,"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218519,"gmtCreate":1620622832331,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218519","repostId":"1171756066","repostType":4,"repost":{"id":"1171756066","kind":"news","pubTimestamp":1620614586,"share":"https://www.laohu8.com/m/news/1171756066?lang=&edition=full","pubTime":"2021-05-10 10:43","market":"us","language":"en","title":"5 Unbeatable Stocks to Buy for a Biden Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1171756066","media":"fool","summary":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019  pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional","content":"<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.</p>\n<p>However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.</p>\n<p>If a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.</p>\n<p><b>Alphabet</b></p>\n<p>Few stocks are more synonymous with the word \"unbeatable\" than&nbsp;<b>Alphabet</b>(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.</p>\n<p>Alphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,<b>Microsoft</b>'s Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.</p>\n<p>But Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.</p>\n<p>Despite its $1.6 trillion price tag, Alphabet is still a bargain.</p>\n<p><b>AstraZeneca</b></p>\n<p>For two decades,pharmaceutical stock&nbsp;<b>AstraZeneca</b>(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.</p>\n<p>The primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.</p>\n<p>Equally exciting is AstraZeneca's pending acquisition of<b>Alexion Pharmaceuticals</b>(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.</p>\n<p>The best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.</p>\n<p><b>Mastercard</b></p>\n<p>Another unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitator<b>Mastercard</b>(NYSE:MA).</p>\n<p>Like mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.</p>\n<p>Something else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.</p>\n<p>The math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.</p>\n<p><b>Annaly Capital Management</b></p>\n<p>Don't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)<b>Annaly Capital Management</b>(NYSE:NLY)could be a smart place to put your money to work.</p>\n<p>Without getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.</p>\n<p>What makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.</p>\n<p>Additionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.</p>\n<p><b>Trupanion</b></p>\n<p>Lastly, companion animal health insurance company&nbsp;<b>Trupanion</b>(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.</p>\n<p>The pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.</p>\n<p>Trupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.</p>\n<p>This is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.</p>\n<p>The sky is the limit for Trupanion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Unbeatable Stocks to Buy for a Biden Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Unbeatable Stocks to Buy for a Biden Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","MA":"万事达","TRUP":"Trupanion","NLY":"Annaly Capital Management","GOOGL":"谷歌A"},"source_url":"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171756066","content_text":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.\nHowever, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.\nIf a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.\nAlphabet\nFew stocks are more synonymous with the word \"unbeatable\" than Alphabet(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.\nAlphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,Microsoft's Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.\nBut Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.\nDespite its $1.6 trillion price tag, Alphabet is still a bargain.\nAstraZeneca\nFor two decades,pharmaceutical stock AstraZeneca(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.\nThe primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.\nEqually exciting is AstraZeneca's pending acquisition ofAlexion Pharmaceuticals(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.\nThe best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.\nMastercard\nAnother unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitatorMastercard(NYSE:MA).\nLike mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.\nSomething else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.\nThe math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.\nAnnaly Capital Management\nDon't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)Annaly Capital Management(NYSE:NLY)could be a smart place to put your money to work.\nWithout getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.\nWhat makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.\nAdditionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.\nTrupanion\nLastly, companion animal health insurance company Trupanion(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.\nThe pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.\nTrupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.\nThis is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.\nThe sky is the limit for Trupanion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218621,"gmtCreate":1620622817563,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218621","repostId":"1134875250","repostType":4,"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105638330,"gmtCreate":1620296481120,"gmtModify":1631893073913,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[{"img":"https://static.tigerbbs.com/643561680a48d73f90dc683d5e373774","width":"1080","height":"2691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105638330","isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105631760,"gmtCreate":1620296458450,"gmtModify":1631893073917,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","text":"$Sundial Growers Inc.(SNDL)$nnice","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631760","isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":105631204,"gmtCreate":1620296431108,"gmtModify":1631893073919,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","text":"$Sundial Growers Inc.(SNDL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631204","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102863555,"gmtCreate":1620194457977,"gmtModify":1631893073925,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","text":"$Sundial Growers Inc.(SNDL)$nive nice","images":[{"img":"https://static.tigerbbs.com/0b2eb12693b8f6ecf14229e9a566de49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102863555","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102869447,"gmtCreate":1620194334889,"gmtModify":1631893073925,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice nice","listText":"Nice nice","text":"Nice nice","images":[{"img":"https://static.tigerbbs.com/f6ef167bf6935202904379daf636071a","width":"1080","height":"2691"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/102869447","isVote":1,"tweetType":1,"viewCount":265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":368156004,"gmtCreate":1614302382008,"gmtModify":1703476041201,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>haha","listText":"<a href=\"https://laohu8.com/S/AMC\">$AMC Entertainment(AMC)$</a>haha","text":"$AMC Entertainment(AMC)$haha","images":[{"img":"https://static.tigerbbs.com/d7b5a27826090295ac3ca5c3d6ebd698","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/368156004","isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":382950420,"gmtCreate":1613353383160,"gmtModify":1631885327525,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a>im doing surprisingly well","listText":"<a href=\"https://laohu8.com/S/RIOT\">$Riot Blockchain, Inc.(RIOT)$</a>im doing surprisingly well","text":"$Riot Blockchain, Inc.(RIOT)$im doing surprisingly well","images":[{"img":"https://static.tigerbbs.com/13b2efd3951a065e2862250421ce2c85","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/382950420","isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":314678300,"gmtCreate":1612349123000,"gmtModify":1703760658543,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a><a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>GME + SNDL","listText":"<a href=\"https://laohu8.com/S/GME\">$GameStop(GME)$</a><a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>GME + SNDL","text":"$GameStop(GME)$$Sundial Growers Inc.(SNDL)$GME + SNDL","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/314678300","isVote":1,"tweetType":1,"viewCount":852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":161221259,"gmtCreate":1623929962671,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nice nieci","text":"$Sundial Growers Inc.(SNDL)$nice nieci","images":[{"img":"https://static.tigerbbs.com/fab74b2cd1a99b5693d5411f077730f3","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/161221259","isVote":1,"tweetType":1,"viewCount":1381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":190216986,"gmtCreate":1620622845345,"gmtModify":1631890890054,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/190216986","repostId":"2134686276","repostType":4,"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105631760,"gmtCreate":1620296458450,"gmtModify":1631893073917,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice","text":"$Sundial Growers Inc.(SNDL)$nnice","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631760","isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":344073267,"gmtCreate":1618363341759,"gmtModify":1631888190396,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FNGU\">$Bank Of Montreal(FNGU)$</a>nnice","listText":"<a href=\"https://laohu8.com/S/FNGU\">$Bank Of Montreal(FNGU)$</a>nnice","text":"$Bank Of Montreal(FNGU)$nnice","images":[{"img":"https://static.tigerbbs.com/a52afd16493a963c981d2d66929df3c7","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/344073267","isVote":1,"tweetType":1,"viewCount":208,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":381174533,"gmtCreate":1612949907822,"gmtModify":1703767308875,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>humble brag","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>humble brag","text":"$Sundial Growers Inc.(SNDL)$humble brag","images":[{"img":"https://static.tigerbbs.com/a8588c3799b2ac0de1afffaae30d1d64","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/381174533","isVote":1,"tweetType":1,"viewCount":423,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":163050271,"gmtCreate":1623854239793,"gmtModify":1631890890041,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163050271","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00467":"联合能源集团","MOLN":"Molecular Partners AG","00626":"大众金融控股","UBCP":"联合合众银行","AFG":"美国金融集团有限公司"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":846,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":163027475,"gmtCreate":1623854226797,"gmtModify":1631890890044,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Good good","listText":"Good good","text":"Good good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/163027475","repostId":"2143879474","repostType":4,"repost":{"id":"2143879474","kind":"news","pubTimestamp":1623853920,"share":"https://www.laohu8.com/m/news/2143879474?lang=&edition=full","pubTime":"2021-06-16 22:32","market":"us","language":"en","title":"Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2143879474","media":"ACCESSWIRE","summary":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a cli","content":"<p><b>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / </b><a href=\"https://laohu8.com/S/MOLN\">Molecular Partners AG</a> (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent <a href=\"https://laohu8.com/S/AONE\">one</a> Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.</p>\n<p>Trading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.</p>\n<p>On June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.</p>\n<p>The offering is expected to close on or about June 18, 2021, subject to customary closing conditions.</p>\n<p>J.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen &amp; Co is acting as the lead manager for the proposed offering.</p>\n<p>A registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.</p>\n<h4>About Molecular Partners AG</h4>\n<p>Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMolecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 22:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® ...</p>\n\n<a href=\"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"00467":"联合能源集团","MOLN":"Molecular Partners AG","00626":"大众金融控股","UBCP":"联合合众银行","AFG":"美国金融集团有限公司"},"source_url":"https://finance.yahoo.com/news/molecular-partners-announces-pricing-initial-020000537.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143879474","content_text":"ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the pricing of its initial public offering in the United States of 3,000,000 American Depositary Shares ('ADSs') at a public offering price of $21.25 per ADS, for total gross proceeds of approximately $63.8 million. All ADSs sold in the offering were offered by Molecular Partners. Each ADS will represent one Molecular Partners ordinary share. The new ordinary shares underlying the ADSs will be issued from Molecular Partners' authorized capital under exclusion of the existing shareholders' pre-emptive rights. In addition, Molecular Partners has granted the underwriters a 30-day option to purchase up to an additional 450,000 ADSs at the initial public offering price, less underwriting discounts and commissions.\nTrading of the ADSs is expected to commence on The Nasdaq Global Select Market on Wednesday, June 16, 2021 under the ticker symbol 'MOLN.' SIX Swiss Exchange ('SIX') approved the listing of the new ordinary shares underlying the ADSs as of June 17, 2021.\nOn June 16, 2021, trading of the existing shares of Molecular Partners on SIX will be halted. If trading of the ADS on the Nasdaq will commence at 4 p.m. CEST on June 16, 2021 or any time before, trading of the shares of Molecular Partners on SIX will reopen on the same day. If trading on the Nasdaq starts later, trading of the shares in Molecular Partners on SIX will reopen on June 17, 2021 only.\nThe offering is expected to close on or about June 18, 2021, subject to customary closing conditions.\nJ.P. Morgan, SVB Leerink and Cowen are acting as joint book-running managers for the proposed offering. RBC Capital Markets is acting as the bookrunner for the proposed offering. Kempen & Co is acting as the lead manager for the proposed offering.\nA registration statement on Form F-1 relating to these securities became effective on June 15, 2021. The securities referred to in this release are to be offered only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, a written copy may be obtained for free from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-866-803-9204; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6105, or by e-mailing syndicate@svbleerink.com; Cowen and Company, LLC (c/o Broadridge Financial Services), 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com. The securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. In connection with the listing of the ordinary shares on the SIX, the registration statement on Form F-1 constitutes a foreign prospectus within the meaning of article 54 paras. 2 and 3 of the Swiss Financial Services Act of June 15, 2018 ('FinSA') and article 70 paras. 2-4 of the Swiss Financial Services Ordinance of November 6, 2019 ('FinSO'). The registration statement on Form F-1, including the preliminary prospectus, as well as the final prospectus, once available, will be deposited with the Prospectus Office of SIX Exchange Regulation. Further, the inclusion of the foreign prospectus in the prospectus list published by the Prospectus Office of SIX Exchange Regulation will be requested.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Molecular Partners in or into Switzerland within the meaning of FinSA.\nAbout Molecular Partners AG\nMolecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.","news_type":1},"isVote":1,"tweetType":1,"viewCount":570,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218519,"gmtCreate":1620622832331,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nicely","listText":"Nicely","text":"Nicely","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218519","repostId":"1171756066","repostType":4,"repost":{"id":"1171756066","kind":"news","pubTimestamp":1620614586,"share":"https://www.laohu8.com/m/news/1171756066?lang=&edition=full","pubTime":"2021-05-10 10:43","market":"us","language":"en","title":"5 Unbeatable Stocks to Buy for a Biden Bull Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1171756066","media":"fool","summary":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019  pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional","content":"<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.</p>\n<p>However, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.</p>\n<p>If a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.</p>\n<p><b>Alphabet</b></p>\n<p>Few stocks are more synonymous with the word \"unbeatable\" than&nbsp;<b>Alphabet</b>(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.</p>\n<p>Alphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,<b>Microsoft</b>'s Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.</p>\n<p>But Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.</p>\n<p>Despite its $1.6 trillion price tag, Alphabet is still a bargain.</p>\n<p><b>AstraZeneca</b></p>\n<p>For two decades,pharmaceutical stock&nbsp;<b>AstraZeneca</b>(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.</p>\n<p>The primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.</p>\n<p>Equally exciting is AstraZeneca's pending acquisition of<b>Alexion Pharmaceuticals</b>(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.</p>\n<p>The best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.</p>\n<p><b>Mastercard</b></p>\n<p>Another unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitator<b>Mastercard</b>(NYSE:MA).</p>\n<p>Like mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.</p>\n<p>Something else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.</p>\n<p>The math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.</p>\n<p><b>Annaly Capital Management</b></p>\n<p>Don't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)<b>Annaly Capital Management</b>(NYSE:NLY)could be a smart place to put your money to work.</p>\n<p>Without getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.</p>\n<p>What makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.</p>\n<p>Additionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.</p>\n<p><b>Trupanion</b></p>\n<p>Lastly, companion animal health insurance company&nbsp;<b>Trupanion</b>(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.</p>\n<p>The pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.</p>\n<p>Trupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.</p>\n<p>This is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.</p>\n<p>The sky is the limit for Trupanion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Unbeatable Stocks to Buy for a Biden Bull Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Unbeatable Stocks to Buy for a Biden Bull Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-10 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","MA":"万事达","TRUP":"Trupanion","NLY":"Annaly Capital Management","GOOGL":"谷歌A"},"source_url":"https://www.fool.com/investing/2021/05/09/5-unbeatable-stocks-to-buy-for-a-biden-bull-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171756066","content_text":"When President Joe Biden took office on Jan. 20, 2021, he inherited one of the worst economic catastrophes in decades. The coronavirus disease 2019 (COVID-19) pandemic wreaked havoc on the U.S. and global economy, and it briefly sent the U.S. stock market into a tailspin.\nHowever, a perfect storm could be brewing for equities under the Biden administration. The Federal Reserve has pledged to hold firm on historically low lending rates, while the White House is calling for trillions of dollars in additional spending. This abundant access to cheap capital is the perfect recipe for stocks to thrive in a rebounding economy.\nIf a Biden bull market does take shape, the following five unbeatable stocks would be the perfect companies to own.\nAlphabet\nFew stocks are more synonymous with the word \"unbeatable\" than Alphabet(NASDAQ:GOOGL)(NASDAQ:GOOG), the parent company of internet search engine Google and streaming platform YouTube.\nAlphabet operates what might as well be a monopoly in internet search. According to GlobalStats, Google has consistently maintainedglobal search engine market share of 91% to 93%for at least the past two years. Its next-closest competitor,Microsoft's Bing, hardly registered with a 2.29% share of the search engine market in April 2021. Being such a dominant force in search means advertisers will pay up for prime placement. It also suggests that the company's traffic acquisition costs should decline over time. As the U.S. and global economy improve, ad spending should really pick up.\nBut Alphabetis about more than just internet search. Ad revenue generated from YouTube -- one of the three most-visited social sites on the planet -- jumped 49% in the first quarter to $6 billion. Meanwhile, revenue from cloud infrastructure segment Google Cloud rose 46% to $4 billion. These once small ancillary operations are now on track to contribute $40 billion in sales to Alphabet on an annual run-rate basis.\nDespite its $1.6 trillion price tag, Alphabet is still a bargain.\nAstraZeneca\nFor two decades,pharmaceutical stock AstraZeneca(NASDAQ:AZN)was a largely forgettable drug developer that struggled with competition and the patent cliff. Today, it's reinvented itself into a bona fide growth stock with a bright future.\nThe primary growth driver for AstraZenecais the company's oncology segment. In the first quarter alone, constant currency sales jumped 16% to $3.02 billion. The company's blockbuster trio of Tagrisso, Imfinzi, and Lynparza led the way with respective constant-currency sales growth of 13%, 17%, and 33%. Diabetes blockbuster drug Farxiga also deserves a mention with its 50% constant-currency sales growth in Q1 2021. The company's brand-name treatments are on fire, and it's led to sustainable double-digit topline growth.\nEqually exciting is AstraZeneca's pending acquisition ofAlexion Pharmaceuticals(NASDAQ:ALXN). Alexion is a developer of ultra-rare therapeutics. Though it's risky developing treatments for such a small group of patients, success is usually met with no competition and little or no pushback from health insurers on high list prices.\nThe best part about the Alexion deal is the companydeveloped a replacement for its top-selling drug, Soliris. The next-generation therapy, known as Ultomiris, is administered less frequently, which is a positive for patients. Eventually, Ultomiris will gobble up Soliris' sales and lock-up Alexion's/AstraZeneca's cash flow for a long time to come.\nMastercard\nAnother unbeatable stock that can deliver superior returns with Biden in the White House is payment facilitatorMastercard(NYSE:MA).\nLike mostfinancial stocks, Mastercard is cyclical. This means it struggles when the U.S. and global economy contract or enter a recession and it thrives when the economy is running on all cylinders. That's because it relies on merchant fees via payments to drive its top and bottom line. But the thing to understand about cyclical companies like Mastercard is that time is on their side. Whereas recessions often last for a few quarters, periods of expansion usually last many years. Considering how much money the Biden administration is attempting to pump into the U.S. economy, Mastercard should have a field day.\nSomething else to consider is that Mastercardhas chosen not to be a lender. Although some of its peers do act as both processors and lenders (via credit cards), and are therefore able to double-dip during economic expansions, Mastercard's avoidance of lending is actually a smart move. When recessions inevitably strike and credit delinquencies rise, Mastercard doesn't have set aside cash. This is why it rebounds much quicker than its peers during the early stages of a recovery.\nThe math here is simple: As the economy picks up steam, consumers and businesses are going to spend, spend, and spend some more. That's music to the ears of all Mastercard shareholders.\nAnnaly Capital Management\nDon't worry, I haven't forgotten about you dividend income-seekers out there. If a Biden bull market takes shape, mortgage real estate investment trust (REIT)Annaly Capital Management(NYSE:NLY)could be a smart place to put your money to work.\nWithout getting overly technical, mortgage REITs like Annaly borrow money at short-term lending rates and use it to purchase securities with higher long-term yields. In Annaly's case, we're primarily talking about mortgage-backed securities (MBS). The difference between the long-term yield received and the short-term borrowing rate is known as net interest margin (NIM). The wider the NIM, the more profitable Annaly is, and the bigger the dividend payout it can provide to shareholders. Right now, Annaly Capital isyielding a jaw-dropping 9.7%.\nWhat makes Annaly such a perfect stock to buy is thatwe're witnessing the yield curve steepen. When the U.S. economy is rebounding from a recession, it's normal for long-term yields to rise and for short-term yields to fall or flatten out. When this happens, Annaly usually experiences a widening of its NIM.\nAdditionally, Annaly almost exclusively buys agency securities. This is a fancy way of saying that the MBSs it's purchasing are backed by the federal government in the event of a default. This protection is what allows the company to utilize leverage to its advantage, thereby pumping up its profits.\nTrupanion\nLastly, companion animal health insurance company Trupanion(NASDAQ:TRUP)has all the look of an unbeatable stock to buy in a Biden bull market.\nThe pet industry may not offer flashy growth prospects like cybersecurity or cannabis, but it's arguably themost consistent growth opportunity. It's been more than a quarter of a century since year-over-year U.S. pet expenditures declined. Further, the American Pet Products Association notes that the percentage of American household owning a pet has increased from 56% in 1988 to 67% by 2019-2020. If we've learned anything about pet owners, it's that they're willing to spend big bucks to ensure the well-being of their four-legged family members.\nTrupanion, which recently lifted the hood on its first-quarter operating results, isclosing in on 1 million total enrolled pets(943,854 at the end of Q1 2021). Amazingly, this only represents a little over 1% penetration of the U.S. market. In the U.K., about 1 in 4 pet owners purchases insurance for their cat or dog. If Trupanion can achieve a similar penetration rate, its addressable market would be more than $32 billion.\nThis is a company that's spent two decades building up rapport with veterinarians and their staff at the clinical level. It's also the only major companion animal health insurance provider with software capable of handling payment to veterinarians at the time of checkout.\nThe sky is the limit for Trupanion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190218621,"gmtCreate":1620622817563,"gmtModify":1631890890062,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/190218621","repostId":"1134875250","repostType":4,"isVote":1,"tweetType":1,"viewCount":247,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":105631204,"gmtCreate":1620296431108,"gmtModify":1631893073919,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nnice nieci","text":"$Sundial Growers Inc.(SNDL)$nnice nieci","images":[{"img":"https://static.tigerbbs.com/bede97e5c63296fec9f742656d9a64a1","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/105631204","isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":102863555,"gmtCreate":1620194457977,"gmtModify":1631893073925,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","listText":"<a href=\"https://laohu8.com/S/SNDL\">$Sundial Growers Inc.(SNDL)$</a>nive nice","text":"$Sundial Growers Inc.(SNDL)$nive nice","images":[{"img":"https://static.tigerbbs.com/0b2eb12693b8f6ecf14229e9a566de49","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102863555","isVote":1,"tweetType":1,"viewCount":456,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":325940836,"gmtCreate":1615859515925,"gmtModify":1703494085397,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/325940836","repostId":"1124726208","repostType":4,"repost":{"id":"1124726208","kind":"news","pubTimestamp":1615854446,"share":"https://www.laohu8.com/m/news/1124726208?lang=&edition=full","pubTime":"2021-03-16 08:27","market":"us","language":"en","title":"Elon Musk Is Now the ‘Technoking’ of Tesla. What’s Behind the Name.","url":"https://stock-news.laohu8.com/highlight/detail?id=1124726208","media":"Barrons","summary":"Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla . CFO Zach Kirkhorn is getting another one, too: Master of Coin.In the SEC 8-K filing, Kirkhorn adds: “Elon and Zach will also maintain their respective positions as Chief Executive Officer and Chief Financial Officer.”The new titles might reflect the men’s decision to put some of Tesla’s cash into B","content":"<p>Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.</p><p>The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla (ticker: TSLA). CFO Zach Kirkhorn is getting another one, too: Master of Coin.</p><p>In the SEC 8-K filing, Kirkhorn adds: “Elon and Zach will also maintain their respective positions as Chief Executive Officer and Chief Financial Officer.”</p><p>An 8-K form is what companies file to notify shareholders of important information, such as earnings news releases, management appointments and corporate acquisitions.</p><p>The new titles might reflect the men’s decision to put some of Tesla’s cash&nbsp;into Bitcoin. The cryptocurrency hit $60,000 over the weekend, making the EV maker more than&nbsp;$1 billion&nbsp;on its initial $1.5 billion buy. Tesla invested back when Bitcoin was about $33,000.</p><p>Bitcoin has fallen back in Monday trading to about $56,000, but is still up more than 90% year to date and more than 20% in March.</p><p>Musk spent part of his weekend tweeting about another of his favorite cryptocurrencies, Dogecoin, which is up to a little more than a nickel a Dogecoin—roughly about 1,300% year to date.</p><p>Institutional investors are playing a major role in Bitcoin's recent uptick. Here's why, and what it means for the future.</p><p>The Technoking and Master of Coin titles fall in line with Tesla’s offbeat approach. Musk has turned Tesla into the most valuable car company in the world by, essentially, paying no attention to what traditional automotive companies and analysts say.</p><p>Still, the news isn’t doing much to Tesla stock, which is up about 2%&nbsp;on&nbsp;Monday.S&amp;P 500&nbsp;and&nbsp;Dow Jones Industrial Average&nbsp;futures are up about 0.7% and 0.5%, respectively.</p><p>Investors are really waiting for the Federal Reserve to comment on interest rates later in the week. The U.S. 10 Year Treasury bond yield is up to about 1.6% from 1.2% only a few weeks back. The rapid rise has hit growth stocks, including Tesla shares. The&nbsp;Nasdaq Composite,home to many richly valued, high-growth stocks, is down about 5% since Feb. 16, when the index hit an all-time high. The Dow is up about 4% over the same period.</p><p>Tesla stock is down about 13% since then. Higher rate&nbsp;shit high-growth stocks&nbsp;harder than others. They make it more expensive to finance growth like what Mush is targeting—vehicle delivery growth a year on average for the foreseeable future.</p><p>What’s more, growth companies generate cash far in the future which is worth a little less, relatively speaking, when investors have other options to earn higher rates of interest today.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elon Musk Is Now the ‘Technoking’ of Tesla. What’s Behind the Name.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElon Musk Is Now the ‘Technoking’ of Tesla. What’s Behind the Name.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 08:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/teslas-elon-musk-adds-a-title-and-tells-the-sec-about-it-51615816265?mod=hp_DAY_4><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla (...</p>\n\n<a href=\"https://www.barrons.com/articles/teslas-elon-musk-adds-a-title-and-tells-the-sec-about-it-51615816265?mod=hp_DAY_4\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/teslas-elon-musk-adds-a-title-and-tells-the-sec-about-it-51615816265?mod=hp_DAY_4","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1124726208","content_text":"Tesla’s Elon Musk isn’t only a CEO. On Monday, he became a king of sorts.The electric vehicle pioneer toldthe Securities and Exchange Commissionthat founderMuskwill add the title Technoking of Tesla (ticker: TSLA). CFO Zach Kirkhorn is getting another one, too: Master of Coin.In the SEC 8-K filing, Kirkhorn adds: “Elon and Zach will also maintain their respective positions as Chief Executive Officer and Chief Financial Officer.”An 8-K form is what companies file to notify shareholders of important information, such as earnings news releases, management appointments and corporate acquisitions.The new titles might reflect the men’s decision to put some of Tesla’s cash into Bitcoin. The cryptocurrency hit $60,000 over the weekend, making the EV maker more than $1 billion on its initial $1.5 billion buy. Tesla invested back when Bitcoin was about $33,000.Bitcoin has fallen back in Monday trading to about $56,000, but is still up more than 90% year to date and more than 20% in March.Musk spent part of his weekend tweeting about another of his favorite cryptocurrencies, Dogecoin, which is up to a little more than a nickel a Dogecoin—roughly about 1,300% year to date.Institutional investors are playing a major role in Bitcoin's recent uptick. Here's why, and what it means for the future.The Technoking and Master of Coin titles fall in line with Tesla’s offbeat approach. Musk has turned Tesla into the most valuable car company in the world by, essentially, paying no attention to what traditional automotive companies and analysts say.Still, the news isn’t doing much to Tesla stock, which is up about 2% on Monday.S&P 500 and Dow Jones Industrial Average futures are up about 0.7% and 0.5%, respectively.Investors are really waiting for the Federal Reserve to comment on interest rates later in the week. The U.S. 10 Year Treasury bond yield is up to about 1.6% from 1.2% only a few weeks back. The rapid rise has hit growth stocks, including Tesla shares. The Nasdaq Composite,home to many richly valued, high-growth stocks, is down about 5% since Feb. 16, when the index hit an all-time high. The Dow is up about 4% over the same period.Tesla stock is down about 13% since then. Higher rate shit high-growth stocks harder than others. They make it more expensive to finance growth like what Mush is targeting—vehicle delivery growth a year on average for the foreseeable future.What’s more, growth companies generate cash far in the future which is worth a little less, relatively speaking, when investors have other options to earn higher rates of interest today.","news_type":1},"isVote":1,"tweetType":1,"viewCount":191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329901987,"gmtCreate":1615195520449,"gmtModify":1703485469277,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/329901987","repostId":"2117651365","repostType":4,"isVote":1,"tweetType":1,"viewCount":321,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320469092,"gmtCreate":1615168716916,"gmtModify":1703485110166,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/320469092","repostId":"2117639609","repostType":4,"isVote":1,"tweetType":1,"viewCount":113,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":320460591,"gmtCreate":1615168702213,"gmtModify":1703485109821,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/320460591","repostId":"1169596583","repostType":4,"repost":{"id":"1169596583","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1614958557,"share":"https://www.laohu8.com/m/news/1169596583?lang=&edition=full","pubTime":"2021-03-05 23:35","market":"us","language":"en","title":"Palantir plunged more than 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169596583","media":"老虎资讯综合","summary":"(March 5)&nbsp;Palantir plunged more than 13%.","content":"<p>(March 5)&nbsp;Palantir plunged more than 13%.</p><p><img src=\"https://static.tigerbbs.com/13f756ec57cca85c31b6be070941d7c1\" tg-width=\"1059\" tg-height=\"499\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palantir plunged more than 13%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalantir plunged more than 13%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-05 23:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(March 5)&nbsp;Palantir plunged more than 13%.</p><p><img src=\"https://static.tigerbbs.com/13f756ec57cca85c31b6be070941d7c1\" tg-width=\"1059\" tg-height=\"499\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169596583","content_text":"(March 5) Palantir plunged more than 13%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":338,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":365633654,"gmtCreate":1614733495878,"gmtModify":1703480415259,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[{"img":"https://static.tigerbbs.com/b30618556d21a99e71177bbe50075def","width":"1080","height":"2663"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/365633654","isVote":1,"tweetType":1,"viewCount":229,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":361808646,"gmtCreate":1614217655485,"gmtModify":1634550663410,"author":{"id":"3571619533976102","authorId":"3571619533976102","name":"TomCl","avatar":"https://static.tigerbbs.com/84c9633e30b56b9ef4c30ab8c67857b3","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571619533976102","authorIdStr":"3571619533976102"},"themes":[],"htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/361808646","repostId":"2114392599","repostType":2,"isVote":1,"tweetType":1,"viewCount":262,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}